Clinical Trials

36 enrolled

BreastThoracic

Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04890613 2026-06-08

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

BreastGastrointestinalGenitourinaryGynecologic

52 enrolled

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT06312176 2026-06-08

MK-2870-010

1,200 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

NCT03417115 2026-06-05

OPAL

Recruiting

6,150 enrolled

Breast Neoplasms

NCT06257264 2026-06-05

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

BreastGastrointestinalGenitourinaryGynecologicThoracic

103 enrolled

Urinary Bladder Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT06570031 2026-06-05

ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer

Phase 1 Completed

46 enrolled

Breast Neoplasms, Neoplasm Metastasis, Recurrence

NCT07007559 2026-06-05

ASPEN-09-03

120 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT07383506 2026-06-05

A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

Phase NA Not yet recruiting

90 enrolled

BreastGynecologic

Breast Neoplasms, Endometrial Neoplasms

NCT07629206 2026-06-05

Post-Marketing Study for Early-Stage Low-Risk Breast Cancer Treatment Using ProSense® Cryoablation (ChoICE Trial)

400 enrolled

Breast Neoplasms, Neoplasms

NCT05232916 2026-06-04

FLAMINGO-01

750 enrolled

Breast Neoplasms, Neoplasm, Residual

NCT05386108 2026-06-04

ELECTRA

73 enrolled

BreastCNS

Brain Diseases, Brain Neoplasms, Breast Diseases, Breast Neoplasms, Central Nervous System Diseases, Neoplasms, Neoplasms by Site, Central Nervous System Neoplasms

NCT05768139 2026-06-04

PIKALO-1

BreastGynecologicHead & Neck

880 enrolled

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT05870579 2026-06-04

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

48 enrolled

Breast Neoplasms

NCT06253871 2026-06-04

A Phase 1/1b Study of IAM1363 in HER2 Cancers

BreastCNSGastrointestinalThoracic

383 enrolled

Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms, Stomach Neoplasms

NCT06274515 2026-06-04

REMERGE

Phase 4 Recruiting

320 enrolled

Breast Neoplasms

NCT06756932 2026-06-04

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

120 enrolled

Breast Neoplasms

NCT06760819 2026-06-04

panSOHO

BreastGastrointestinalGenitourinaryGynecologicSarcoma

111 enrolled

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors

NCT07174336 2026-06-04

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

920 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT07213791 2026-06-04

FiREBOLT

BreastGastrointestinalGynecologic

241 enrolled

Pancreatic Intraductal Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT07288359 2026-06-04

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

205 enrolled

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT04567420 2026-06-03

DARE

70 enrolled

Breast Neoplasms

NCT05579366 2026-06-03

RAINFOL-01

BreastGynecologicOther solid neoplasmThoracic

884 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Fallopian Tube Neoplasms, Mesothelioma, Ovarian Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05827081 2026-06-03

Adjuvant WIDER

1,400 enrolled

Breast Neoplasms, Breast Neoplasms, Male

NCT06790693 2026-06-03

INAVO123

450 enrolled

Breast Neoplasms

NCT07038369 2026-06-03

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

BreastGenitourinaryGynecologic

134 enrolled

Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Ovarian Neoplasms, Prostatic Neoplasms, Urogenital Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT07114601 2026-06-03

OMNIRAY

BreastGastrointestinalGenitourinaryGynecologic

421 enrolled

Breast Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT07214662 2026-06-03

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer

136 enrolled

Breast Neoplasms

NCT07222267 2026-06-03

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

86 enrolled

Breast Neoplasms

NCT07310420 2026-06-03

A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer

88 enrolled

Breast Neoplasms

NCT07311993 2026-06-03

Phase 1 Study of CLR 125 in Triple Negative Breast Cancer

60 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04916509 2026-06-02

Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region

258 enrolled

Breast Neoplasms

NCT05417594 2026-06-02

CERTIS1

BreastCNSGastrointestinalGenitourinaryGynecologic

695 enrolled

Astrocytoma, Breast Neoplasms, Fallopian Tube Neoplasms, Glioma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT05505175 2026-06-02

Outcomes Among Patients in Brazil Receiving Palbociclib Combinations for HR+/HER2- MBC

121 enrolled

Breast Neoplasms

NCT05709158 2026-06-02

A Study to Learn About the Dangers Linked to Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal Bow Sai Klib)

4,184 enrolled

Breast Neoplasms

NCT05787587 2026-06-02

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

216 enrolled

Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related, Breast Neoplasms, Head and Neck Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06018337 2026-06-02

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

Phase 3 Active not recruiting

541 enrolled

Breast Neoplasms

NCT06369831 2026-06-02

HERMIA

60 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT06624020 2026-06-02

ROSIE

1,128 enrolled

Breast Neoplasms

NCT07354022 2026-06-02

A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.

912 enrolled